Structure-based design of peptide inhibitors of botulinum neurotoxin serotype A proteolytic activity

Botulinum Journal

Volumn 1, Issue 3, 2009, Pages 297-308

  Ludivico, Matthew L ^a   Smith, Leonard A ^b   Ahmed, S Ashraf ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b U S ARMY MEDICAL RESEARCH AND MATERIEL COMMAND   (United States)

Author keywords

Arginine hydroxamate; Basic tetrapeptides; Botulinum neurotoxin catalytic domain; Botulinum neurotoxin inhibitors; Peptide inhibitors; Protease inhibitors; Tetrapeptide inhibitors

Indexed keywords

ALPHA GUANIDINO GLUTARATE; AMINO ACID DERIVATIVE; AMINOLEVULINIC ACID; AMINOPEPTIDASE B; ARGININE DERIVATIVE; ARGINYLARGINYLGLYCYLCYSTEINE; BOTULINUM TOXIN A; DEXTRO ARGININE; DEXTRO ARGININE HYDROXAMATE; DEXTRO CYSTEINE; DEXTRO LEVO ASPARTATE HYDROXAMATE; DEXTRO LEVO METHIONINE HYDROXAMATE; DEXTRO LEVO PHENYLALANINE HYDROXAMATE; DEXTRO LEVO TRYPTOPHAN HYDROXAMATE; DEXTRO LYSINE HYDROXAMATE; GLUTAMYL AMINOPEPTIDASE; GUANIDINE DERIVATIVE; GUANIDINE THIOCYANATE; GUANIDINO SUCCINATE; LEVO ARGININE HYDROXAMATE; LEVO GLUTAMATE GAMMA HYDROXAMATE; LEVO LYSINE HYDROXAMATE; LEVO TYROSINE HYDROXAMATE; METALLOTHIONEIN; NEUROTOXIN; NICOTINIC ACID HYDROXAMATE; PROTAMINE SULFATE; TETRAPEPTIDE; THIOGLYCOLIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CATALYSIS; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG DESIGN; DRUG SCREENING; DRUG STRUCTURE; ENANTIOMER; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME SUBSTRATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PROTEIN DEGRADATION; PROTEIN DOMAIN; SEROTYPE;

EID: 78751549180     PISSN: 17547326     EISSN: 17547318     Source Type: Journal    
DOI: 10.1504/TBJ.2009.031681     Document Type: Article

References (35)

1. Adler, M., Nicholson, J.D., Cornille, F. and Hackley Jr., B.E. (1998) 'Efficacy of a novel metalloprotease inhibitor on botulinum neurotoxin B activity', FEBS Lett., Vol. 429, pp.234-238. (Pubitemid 28300367)
2. Ahmed, S.A. and Smith, L.A. (2000) 'Light chain of botulinum A neurotoxin expressed as an inclusion body from a synthetic gene is catalytically and functionally active', J. Protein Chem., Vol. 19, pp.475-487. (Pubitemid 32043069)
3. Ahmed, S.A., Byrne, M.P., Jensen, M., Hines, H.B., Brueggemann, E. and Smith, L.A. (2001) 'Enzymatic autocatalysis of botulinum A neurotoxin light chain', J. Protein Chem., Vol. 20, pp.221-231.
4. Ahmed, S.A., Mcphie, P. and Smith, L.A. (2003) 'Autocatalytically fragmented light chain of botulinum A neurotoxin is enzymatically active', Biochemistry, Vol. 42, pp.12539-12549. (Pubitemid 37337544)
5. Ahmed, S.A., Olson, M.A., Ludivico, M.L., Gilsdorf, J. and Smith, L.A. (2008) 'Identification of residues surrounding the active site of type a botulinum neurotoxin important for substrate recognition and catalytic activity', Protein J., Vol. 27, pp.151-162. (Pubitemid 351652551)
6. Albini, A., Benelli, R., Giunciuglio, D., Cai, T., Mariani, G., Ferrini, S. and Noonan, D.M. (1998) 'Identification of a novel domain of HIV tat involved in monocyte chemotaxis', J. Biol. Chem., Vol. 273, pp.15895-15900. (Pubitemid 28311351)
7. Alderton, J.M., Ahmed, S.A., Smith, L.A. and Steinhardt, R.A. (2000) 'Evidence for a vesicle-mediated maintenance of store-operated calcium channels in a human embryonic kidney cell line', Cell Calcium, Vol. 28, pp.161-169.
8. Arnon, S.S., Schechter, R., Inglesby, T.V., Henderson, D.A., Bartlett, J.G., Ascher, M.S., Eitzen, E., Fine, A.D., Hauer, J., Layton, M., Lillibridge, S., Osterholm, M.T., O'toole, T., Parker, G., Perl, T.M., Russell, P.K., Swerdlow, D.L. and Tonat, K. (2001) 'Botulinum toxin as a biological weapon: medical and public health management', Jama., Vol. 285, pp.1059-1070. (Pubitemid 32176420)
9. Ayoub, M. and Scheidegger, D. (2006) 'Peptide drugs, overcoming the challenges, a growing business', Chemistry Today, Vol. 24, pp.46-48. (Pubitemid 44475342)
10. Boldt, G.E., Kennedy, J.P., Hixon, M.S., Mcallister, L.A., Barbieri, J.T., Tzipori, S. and Janda, K.D. (2006) 'Synthesis, characterization and development of a high-throughput methodology for the discovery of botulinum neurotoxin a inhibitors', J. Comb. Chem., Vol. 8, pp.513-521. (Pubitemid 44116114)
11. Brin, M.F., Lew, M.F., Adler, C.H., Comella, C.L., Factor, S.A., Jankovic, J., O'brien, C., Murray, J.J., Wallace, J.D., Willmer-Hulme, A. and Koller, M. (1999) 'Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia', Neurology, Vol. 53, pp.1431-1438. (Pubitemid 29491933)
12. Burnett, J.C., Schmidt, J.J., Stafford, R.G., Panchal, R.G., Nguyen, T.L., Hermone, A.R., Vennerstrom, J.L., Mcgrath, C.F., Lane, D.J., Sausville, E.A., Zaharevitz, D.W., Gussio, R. and Bavari, S. (2003) 'Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease activity', Biochem. Biophys. Res. Commun., Vol. 310, pp.84-93. (Pubitemid 37162766)
13. Butler, G.S., Tam, E.M. and Overall, C.M. (2004) 'The canonical methionine 392 of matrix metalloproteinase 2 (gelatinase A) is not required for catalytic efficiency or structural integrity: probing the role of the methionine-turn in the metzincin metalloprotease superfamily', J. Biol. Chem., Vol. 279, pp.15615-15620. (Pubitemid 38618962)
14. Chen, M.D. and Song, Y.M. (2009) 'Tissue metallothionein concentrations in mice and humans with hyperglycemia', Biol. Trace Elem. Res., Vol. 127, pp.251-256.
15. Deshpande, S.S., Sheridan, R.E. and Adler, M. (1995) 'A study of zinc-dependent metalloendopeptidase inhibitors as pharmacological antagonists in botulinum neurotoxin poisoning', Toxicon., Vol. 33, pp.551-557.
16. Fu, Z., Chen, S., Baldwin, M.R., Boldt, G.E., Crawford, A., Janda, K.D., Barbieri, J.T. and Kim, J.J. (2006) 'Light chain of botulinum neurotoxin serotype A: structural resolution of a catalytic intermediate', Biochemistry, Vol. 45, pp.8903-8911. (Pubitemid 44100686)
17. Hamman, J.H., Enslin, G.M. and Kotze, A.F. (2005) 'Oral delivery of peptide drugs: barriers and developments', BioDrugs, Vol. 19, pp.165-177. (Pubitemid 40994232)
18. Harbeson, S.L. and Rich, D.H. (1988) 'Inhibition of arginine aminopeptidase by bestatin and arphamenine analogues. Evidence for a new mode of binding to aminopeptidases', Biochemistry, Vol. 27, pp.7301-7310.
19. Jensen, M.J., Smith, T.J., Ahmed, S.A. and Smith, L.A. (2003) 'Expression, purification, and efficacy of the type A botulinum neurotoxin catalytic domain fused to two translocation domain variants', Toxicon, Vol. 41, pp.691-701. (Pubitemid 36515008)
20. Kumaran, D., Rawat, R., Ahmed, S.A. and Swaminathan, S. (2008a) 'Substrate binding mode and its implication on drug design for botulinum neurotoxin A', PLoS Pathog, Vol. 4, pp.e1000165.
21. Kumaran, D., Rawat, R., Ludivico, M.L., Ahmed, S.A. and Swaminathan, S. (2008b) 'Structure and substrate based inhibitor design for clostridium botulinum neurotoxin serotype A', J. Biol. Chem., Vol. 283, pp.18883-18891.
22. Lacy, D.B., Tepp, W., Cohen, A.C., Dasgupta, B.R. and Stevens, R.C. (1998) 'Crystal structure of botulinum neurotoxin type A and implications for toxicity', Nat. Struct. Biol., Vol. 5, pp.898-902. (Pubitemid 28467413)
23. Marx, V. (2005) 'Watching peptide drugs grow up: Peptide therapeutics market grows in fits and starts for drug firms and contract manufacturers', Chemical and Engineering News, Vol. 83, pp.17-24.
24. Montecucco, C. and Schiavo, G. (1995) 'Structure and function of tetanus and botulinum neurotoxins', Q. Rev. Biophys., Vol. 28, pp.423-472. (Pubitemid 26015975)
25. Schiavo, G., Shone, C.C., Bennett, M.K., Scheller, R.H. and Montecucco, C. (1995) 'Botulinum neurotoxin type C cleaves a single Lys-Ala bond within the carboxyl-terminal region of syntaxins', J. Biol. Chem., Vol. 270, pp.10566-10570.
26. Schmidt, J.J. and Bostian, K.A. (1995) 'Proteolysis of synthetic peptides by type A botulinum neurotoxin', J. Protein Chem., Vol. 14, pp.703-708. (Pubitemid 26006119)
27. Schmidt, J.J. and Bostian, K.A. (1997) 'Endoproteinase activity of type A botulinum neurotoxin: substrate requirements and activation by serum albumin', J. Protein Chem., Vol. 16, pp.19-26. (Pubitemid 27114001)
28. Schmidt, J.J. and Stafford, R.G. (2002) 'A high affinity competitive inhibitor of type A botulinum neurotoxin protease activity', FEBS Lett., Vol. 532, pp.423-426. (Pubitemid 35441386)
29. Schmidt, J.J. and Stafford, R.G. (2005) 'Botulinum neurotoxin serotype F: identification of substrate recognition requirements and development of inhibitors with low nanomolar affinity', Biochemistry, Vol. 44, pp.4067-4073. (Pubitemid 40358059)
30. Silvaggi, N.R., Boldt, G.E., Hixon, M.S., Kennedy, J.P., Tzipori, S., Janda, K.D. and Allen, K.N. (2007) 'Structures of clostridium botulinum neurotoxin serotype a light chain complexed with small-molecule inhibitors highlight active-site flexibility', Chem. Biol., Vol. 14, pp.533-542. (Pubitemid 46765150)
31. Steinhardt, R.A., Bi, G. and Alderton, J.M. (1994) 'Cell membrane resealing by a vesicular mechanism similar to neurotransmitter release', Science, Vol. 263, pp.390-393. (Pubitemid 24067947)
32. Swaminathan, S. and Eswaramoorthy, S. (2000) 'Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B', Nat. Struct. Biol., Vol. 7, pp.693-699. (Pubitemid 30636683)
33. Verheyden, J., Blitzer, A. and Brin, M.F. (2001) 'Other noncosmetic uses of BOTOX', Semin. Cutan. Med. Surg., Vol. 20, pp.121-126. (Pubitemid 32661745)
34. Zalups, R.K. (2000) 'Molecular interactions with mercury in the kidney', Pharmacol Rev., Vol. 52, pp.113-143. (Pubitemid 30127597)
35. Zuniga, J.E., Schmidt, J.J., Fenn, T., Burnett, J.C., Arac, D., Gussio, R., Stafford, R.G., Badie, S.S., Bavari, S. and Brunger, A.T. (2008) 'A potent peptidomimetic inhibitor of botulinum neurotoxin serotype a has a very different conformation than snap-25 substrate', Structure, Vol. 16, pp.1588-1597.